Bio-Path Holdings Company Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge.
The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).
It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML.
Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Vikram Grover |
Contact Details
Address: 4710 Bellaire Boulevard Bellaire, Delaware 77401 United States | |
| Phone | 832 742 1357 |
| Website | biopathholdings.com |
Stock Details
| Ticker Symbol | BPTH |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US09057N3008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas P. Morris | Co-Founder, Chairman, Director of Investor Relations and Secretary |